Aarti Drugs Ltd

Aarti Drugs Ltd

₹ 543 0.26%
29 Sep - close price
About

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]

It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]

Key Points

Largest producer in World
Aarti Drugs Ltd. (ADL) is the largest producer of Fluoroquinolones group, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole in the world. It is one of the leading producers of Metformin in the world. [1]

  • Market Cap 5,024 Cr.
  • Current Price 543
  • High / Low 646 / 311
  • Stock P/E 28.0
  • Book Value 129
  • Dividend Yield 0.18 %
  • ROCE 15.5 %
  • ROE 14.9 %
  • Face Value 10.0

Pros

Cons

  • Promoter holding has decreased over last quarter: -0.88%
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
545 578 530 502 580 580 635 694 622 688 664 742 661
411 462 424 421 500 506 545 608 555 613 593 649 577
Operating Profit 134 116 106 81 80 74 90 86 67 74 71 94 84
OPM % 25% 20% 20% 16% 14% 13% 14% 12% 11% 11% 11% 13% 13%
1 0 2 1 2 0 7 3 0 0 1 1 1
Interest 7 7 5 4 4 5 5 6 7 8 9 9 9
Depreciation 12 13 13 12 12 12 13 13 13 13 13 12 13
Profit before tax 116 97 90 65 65 56 79 70 48 53 50 73 64
Tax % 27% 22% 25% 21% 25% 24% 26% 22% 28% 27% 26% 23% 24%
85 75 68 52 49 43 58 55 35 39 37 56 48
EPS in Rs 9.17 8.08 7.30 5.54 5.27 4.60 6.29 5.98 3.76 4.18 3.96 6.06 5.17
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2009 Mar 2010 Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
382 479 501 1,097 1,140 1,195 1,244 1,561 1,806 2,155 2,489 2,716 2,755
316 396 432 925 960 1,005 1,042 1,350 1,541 1,714 2,156 2,407 2,433
Operating Profit 66 83 69 172 180 190 202 211 266 440 333 309 323
OPM % 17% 17% 14% 16% 16% 16% 16% 14% 15% 20% 13% 11% 12%
0 0 0 1 0 4 1 6 6 5 11 2 3
Interest 26 19 17 42 48 40 38 44 37 26 24 37 35
Depreciation 14 17 19 31 37 38 40 43 49 50 50 50 50
Profit before tax 26 47 33 100 95 116 125 131 185 369 270 224 240
Tax % 33% 40% 29% 23% 28% 29% 34% 32% 24% 24% 24% 26%
17 29 24 77 69 82 82 90 141 280 205 166 180
EPS in Rs 2.92 2.46 7.97 7.09 8.57 8.73 9.52 15.17 30.09 22.14 17.96 19.37
Dividend Payout % 22% 21% 25% 41% 24% 3% 3% 3% 3% 8% 5% 6%
Compounded Sales Growth
10 Years: %
5 Years: 17%
3 Years: 15%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: 15%
3 Years: 6%
TTM: -6%
Stock Price CAGR
10 Years: 37%
5 Years: 31%
3 Years: -11%
1 Year: 16%
Return on Equity
10 Years: %
5 Years: 22%
3 Years: 23%
Last Year: 15%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2009 Mar 2010 Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
12 12 12 24 24 24 24 24 23 93 93 93
Reserves 112 134 151 284 333 376 432 520 629 820 944 1,100
192 189 267 448 483 480 546 507 389 351 543 609
88 84 93 248 261 311 388 405 535 502 629 620
Total Liabilities 403 419 523 1,004 1,102 1,191 1,389 1,455 1,576 1,766 2,208 2,421
205 208 248 448 493 581 602 625 644 665 690 676
CWIP 1 3 10 16 34 14 28 33 12 19 77 210
Investments 2 2 5 5 5 12 11 12 13 17 19 19
196 206 260 534 570 584 748 785 907 1,064 1,422 1,516
Total Assets 403 419 523 1,004 1,102 1,191 1,389 1,455 1,576 1,766 2,208 2,421

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2009 Mar 2010 Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
61 59 21 105 133 175 70 143 251 155 70 134
-8 -30 -76 -107 -99 -107 -74 -62 -33 -72 -150 -164
-54 -24 53 1 -33 -68 4 -80 -215 -81 92 17
Net Cash Flow -1 5 -3 -1 1 -0 0 1 2 2 13 -13

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2009 Mar 2010 Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 108 88 88 105 106 91 110 107 99 94 110 116
Inventory Days 92 77 103 82 86 100 132 86 102 117 115 101
Days Payable 82 60 73 83 90 94 123 85 104 93 103 94
Cash Conversion Cycle 119 105 118 104 103 97 119 109 97 118 123 123
Working Capital Days 127 106 134 98 102 97 122 105 87 110 122 128
ROCE % 16% 20% 13% 18% 18% 17% 17% 21% 34% 21% 15%

Shareholding Pattern

Numbers in percentages

8 Recently
Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023
60.21% 60.20% 60.20% 60.14% 60.12% 59.99% 59.83% 59.98% 59.77% 59.66% 59.57% 58.70%
2.19% 3.06% 2.99% 2.57% 2.21% 2.03% 2.07% 2.07% 1.94% 1.90% 1.94% 1.97%
2.15% 1.68% 1.76% 2.00% 2.12% 2.28% 2.69% 2.76% 3.16% 3.90% 4.09% 4.72%
35.45% 35.07% 35.05% 35.29% 35.55% 35.71% 35.41% 35.19% 35.11% 34.53% 34.39% 34.63%
No. of Shareholders 1,05,5191,51,1601,73,7041,77,9931,83,3441,95,4691,89,6071,86,6741,80,3031,73,2831,69,0901,62,409

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls